ADMA ADMA BIOLOGICS, INC.
Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR ADMA BIOLOGICS, INC. (ADMA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: FDA approval of yield enhancement production process in April 2025 may impact revenue forecasts and operational scaling
- • Most updated risk: Net income of $197.7M in 2024 vs prior losses, with increased operating expenses due to commercialization and R&D expansion
Quarterly Financial SummaryXBRL
Revenue
$134M
Net Income
$36M
Gross Margin
56.3%
Operating Margin
38.0%
Net Margin
27.1%
ROE
8.4%
Total Assets
$569M
Source: XBRL data from ADMA BIOLOGICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ADMA BIOLOGICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.